NCBiotech News

A year-old RTP nonprofit, Med Aditus International, founded by retired UNC pharmacy prof Dhiren R. Thakker, Ph.D., is about to launch a game-changing pharmaceutical manufacturing and training initiative to provide affordable, high-quality medicines in sub-Saharan Africa.

Durham's Bioventus has filed regulatory paperwork outlining a preliminary $100 million target for a proposed initial public stock offering

Belgian food and crop protection company Biotalys NV, with U.S. headquarters in NCBiotech's Landing Pad offices, has just submitted its first product for U.S. Environmental Protection Agency approval.

Durham's Precision Biosciences has received FDA approval to advance its new drug for patients with relapsed/refractory non-Hodgkin Lymphoma.

Durham-based Chimerix priced the stock offering late Wednesday, selling more than 11.7 million shares for $8.50 apiece to raise $100 million that can help bring lead drugs to FDA approval.

Target RWE, a clinical data company based in Durham, has acquired a neighboring software analysis and services company, NoviSci, and scored an investment from California biotech pioneer Amgen.

Global biotherapeutics giant Grifols will soon start a clinical trial for what could become the second approved treatment for COVID-19.

Atsena Therapeutics is a Durham clinical-stage gene therapy company with $63M in the bank so far to propel its mission to reverse and prevent blindness.

A Jan. 28 virtual symposium, “BioGrow: Training and Education Across North Carolina,” is planned to get the word out to anyone interested in a career in biopharmaceuticals.

California gene therapy innovator Adverum Biotechnologies announced plans today to invest some $83 million to establish a manufacturing site in Durham that will employ 202 people through 2026.

Diana De Leon, an 18-year-old recent Pitt County high school grad, is proof that satisfying, rewarding, career-worthy jobs are waiting for a wide range of North Carolinians in the field of pharmaceutical manufacturing. She's now employed at Thermo Fisher Scientific in Greenville.

Ribometrix, a Durham company specializing in RNA-based therapeutics, has formed a drug discovery and development collaboration with Genentech that could be worth more than $1 billion.

Raleigh-based Marius Pharmaceuticals, led by several former GlaxoSmithKline scientists and executives, is making progress on its first potential drug.

Business Facilities magazine, a national publication serving corporate site selectors and economic development professionals, today proclaimed North Carolina the "2020 State of t

Durham's BioCryst Pharmaceuticals is developing its drug galidesivir as a potential treatment for more than 20 RNA viruses. SARS-CoV-2, the virus that causes COVID-19, will no longer be one of them.